<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>47</patient-age><report-id>CA-US-EMD Serono, Inc.-7188377</report-id><gender>female</gender><reactions><reaction>EPISTAXIS</reaction><reaction>MENORRHAGIA</reaction><reaction>INJECTION SITE HAEMORRHAGE</reaction><reaction>THROMBOCYTOPENIA</reaction><reaction>INJECTION SITE HAEMATOMA</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>REBIF</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Elavil</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Tegretol</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10070592</indication></indications><patient-age>47</patient-age><outcomes/><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>PRO000000000000509990</messagenumb>
    <messagesenderidentifier>EMDSERONO</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125161150</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-US-EMD Serono, Inc.-7188377</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>2013-01-25</transmissiondate>
    <reporttype>1</reporttype>
    <serious code="1">Yes</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>2013-01-16</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>2013-01-16</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-Merck KGaA-7188377</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reporterfamilyname>Unknown</reporterfamilyname>
      <reportercountry>CA</reportercountry>
      <qualification code="3">Other Health Professional</qualification>
    </primarysource>
    <sender>
      <senderorganization>US-EMD Serono, Inc.</senderorganization>
      <senderdepartment>US Product Surveillance and Quality Assurance</senderdepartment>
      <sendertitle>Dr</sendertitle>
      <sendergivename>Daryl</sendergivename>
      <senderfamilyname>Dawson</senderfamilyname>
      <senderstreetaddress>One Technology Place</senderstreetaddress>
      <sendercity>Rockland</sendercity>
      <senderstate>MA</senderstate>
      <senderpostcode>02370</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>781-681</sendertel>
      <sendertelextension>2564</sendertelextension>
      <sendertelcountrycode>+1</sendertelcountrycode>
      <senderfax>781-681</senderfax>
      <senderfaxextension>2961</senderfaxextension>
      <senderfaxcountrycode>+1</senderfaxcountrycode>
      <senderemailaddress>usps@emdserono.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>US-A-Food and Drug Administration</receiverorganization>
      <receiverdepartment>AERS</receiverdepartment>
      <receivertitle>Mr</receivertitle>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>CDER</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
      <receivercity>Rockville</receivercity>
      <receiverstate>MD</receiverstate>
      <receiverpostcode>20851</receiverpostcode>
      <receivercountrycode>US</receivercountrycode>
      <receivertel>3017709299</receivertel>
      <receivertelcountrycode>001</receivertelcountrycode>
      <receiverfax>3017706614</receiverfax>
      <receiverfaxcountrycode>001</receiverfaxcountrycode>
      <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
    </receiver>
    <patient lang="en">
      <patientonsetage>47</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex code="2">Female</patientsex>
      <reaction>
        <primarysourcereaction lang="en">EPISTAXIS</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10015090</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10015090</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">MENORRHAGIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10027313</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10027313</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">INJECTION SITE HAEMORRHAGE</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10022067</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022067</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">THROMBOCYTOPENIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10043554</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10043554</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">INJECTION SITE HAEMATOMA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10022066</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022066</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>44</drugstructuredosagenumb>
        <drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
        <drugdosageform normalized="injection">Injection</drugdosageform>
        <drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <actiondrug code="5">Unknown</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10015090</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10015090</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10027313</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10027313</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022067</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022067</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10043554</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10043554</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022066</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022066</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Elavil</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosageform normalized="tablet">Tablet</drugdosageform>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit code="801">Year</drugtreatmentdurationunit>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Tegretol</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <drugtreatmentduration>3</drugtreatmentduration>
        <drugtreatmentdurationunit code="801">Year</drugtreatmentdurationunit>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical>This spontaneous case report from an other healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>in Canada was received via the Canadian Health Authority (Health Canada) (000143822) at Merck Serono on 16 Jan 2013.A 47-year old female patient experienced <Semaphore x="1892716" class="Disease or Finding" value="Epistaxis" score="1.00" ID="C26766">epistaxis</Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, <Semaphore x="2217913" class="Disease or Finding" value="Menorrhagia" score="1.00" ID="C26829">menorrhagia</Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">site </Semaphore>
             </Semaphore></Semaphore>
           </Semaphore>
         <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
          </Semaphore></Semaphore>
        <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
         <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2015671" class="Disease or Finding" value="Hemorrhage" score="1.00" ID="C26791">haemorrhage</Semaphore><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, </Semaphore><Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">thrombocytopenia </Semaphore>and <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore></Semaphore></Semaphore></Semaphore>
       <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
        <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
         <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">
          </Semaphore></Semaphore>
        <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">site </Semaphore></Semaphore></Semaphore>
      <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
       </Semaphore></Semaphore>
     <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
      </Semaphore></Semaphore>
    <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
     </Semaphore>
    <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">haematoma </Semaphore>while being treated with <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.87" ID="249401">Rebif</Semaphore>.The events <Semaphore x="1892716" class="Disease or Finding" value="Epistaxis" score="1.00" ID="C26766">epistaxis</Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, <Semaphore x="2217913" class="Disease or Finding" value="Menorrhagia" score="1.00" ID="C26829">menorrhagia</Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">site </Semaphore>
             </Semaphore></Semaphore>
           </Semaphore>
         <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
          </Semaphore></Semaphore>
        <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
         <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2015671" class="Disease or Finding" value="Hemorrhage" score="1.00" ID="C26791">haemorrhage</Semaphore><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, </Semaphore><Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">thrombocytopenia </Semaphore>and <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore></Semaphore></Semaphore></Semaphore>
       <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
        <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
         <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">
          </Semaphore></Semaphore>
        <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">site </Semaphore></Semaphore></Semaphore>
      <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
       </Semaphore></Semaphore>
     <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
      </Semaphore></Semaphore>
    <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
     </Semaphore>
    <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">haematoma </Semaphore>were assessed as medically significant by the reporter. No relevant <Semaphore x="2210075" class="Procedure" value="Medical Research Council Dyspnea Scale" score="1.00" ID="C21157">medical history was reported</Semaphore>.The patient's concomitant medications included <Semaphore x="524526" class="Medicine" value="Elavil" score="0.49" ID="268181">Elavil </Semaphore>(<Semaphore x="103090" class="Medicine" value="Amitriptyline" score="0.49" ID="280726">amitriptyline</Semaphore>) tablet at a dose of 5.0 mg two times a day from an unspecified date for an unknown indication and <Semaphore x="1250514" class="Medicine" value="TEGretol" score="0.49" ID="241412">Tegretol </Semaphore>(<Semaphore x="300595" class="Medicine" value="Carbamazepine" score="0.49" ID="241093">carbamazepine</Semaphore>) at a dose of 100 mg as required from an unspecified date for an unknown indication.The patient received <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.87" ID="249401">Rebif </Semaphore>(<Semaphore x="735013" class="Medicine" value="Interferon beta-1a" score="0.74" ID="273567"><Semaphore x="735630" class="Medicine" value="Interferon-beta" score="0.49" ID="268564">interferon beta </Semaphore>1a</Semaphore>) at a dose of 44 mcg three times a week subcutaneously from an unspecified date for an unknown indication.On an unspecified date, the patient had <Semaphore x="1892716" class="Disease or Finding" value="Epistaxis" score="1.00" ID="C26766">epistaxis</Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, <Semaphore x="2217913" class="Disease or Finding" value="Menorrhagia" score="1.00" ID="C26829">menorrhagia</Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">site </Semaphore>
             </Semaphore></Semaphore>
           </Semaphore>
         <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
          </Semaphore></Semaphore>
        <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
         <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2015671" class="Disease or Finding" value="Hemorrhage" score="1.00" ID="C26791">haemorrhage</Semaphore><Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, </Semaphore><Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">thrombocytopenia </Semaphore>and <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore></Semaphore></Semaphore></Semaphore>
       <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
        <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
         <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">
          </Semaphore></Semaphore>
        <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">site </Semaphore></Semaphore></Semaphore>
      <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
       </Semaphore></Semaphore>
     <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
      </Semaphore></Semaphore>
    <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067">
     </Semaphore>
    <Semaphore x="3039702" class="MedDRA LLT" value="Injection site haematoma" score="1.00" ID="10022066">haematoma</Semaphore>.At the time of reporting, action taken with <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.87" ID="249401">Rebif </Semaphore>was not reported.At the time of reporting, the events were not recovered.The reporter did not provide any causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment</Semaphore>.</narrativeincludeclinical>
        <sendercomment lang="en">Epistaxis [Epistaxis], menorrhagia [Menorrhagia], injection site haemorrhage [Injection site haemorrhage], thrombocytopenia [Thrombocytopenia] and injection site haematoma [Injection site haematoma] in a 47-year-old female patient while being treated with Rebif. 
Temporal relationship: compatible. Latency: Not assessable (therapy start date and events onset dates not reported). Dechallenge: not applicable (action taken with Rebif therapy not reported).
Alternative explanation: Epistaxis, menorrhagia, injection site haematoma and haemorrhage could be related to the concurrent thrombocytopenia. Concomitant treatment with carbamazepine and amitriptyline could have contributed to the occurrence of this thrombocytopenia.
Evaluation by reporter (healthcare professional): not reported.
Evaluation by company: In absence of sufficient information to fully assess the case, epistaxis, menorrhagia and injection site haemorrhage have been assessed as causally related to Rebif. Thrombocytopenia and injection site haematoma are assessed as related to Rebif.
Epistaxis, Menorrhagia and Injection site haemorrhage are unlisted and Thrombocytopenia and Injection site haematoma are listed for Rebif as per reference safety information. 

Follow-up information has been requested: causality assessment, Rebif therapy details (therapy dates, indication, action taken), events onset dates and values of thrombocytes (severity of thrombocytopenia).</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr></original></faers>